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economical benefit compared to conventional standard EBRT, 
with a saving of 98252.70€ in 75 treated patients. It also 
associates a time profit that may improve QoL. 
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Purpose/Objective: Rationale of accelerated partial breast 
irradiation (APBI) is the prevention of local relapse in breast 
area with the highest probability of recurrences in strictly 
selected patients. Intraoperative Radiotherapy (IORT) is one 
of the most promising techniques of APBI. The aim of this 
study is the preliminary evaluation of toxicity, cosmetic 
effect and 5-years rate of ipsilateral breast recurrences in 
patients treated with exclusive single dose IORT with 
electrons after quadrantectomy (QUAD) for early stage-breast 
cancer. 
Materials and Methods: Between January 2008 and June 
2014 thirty-one women were treated with single dose IORT in 
our Institution. Thirteen were enrolled into a multi-centric 
randomized trial (coordinated by Regina Elena Institute of 
Rome) and eighteen were treated with single dose for age 
and co-morbidities, that contraindicate external beam 
radiotherapy (EBRT). Patients underwent QUAD with sentinel 
lymph node biopsy. All of them were older than 60 years or in 
post-menopausal status, with a single tumour sized 2 cm or 
less, histological proven invasive ductal or lobular carcinoma 
and clinically N0. IORT was delivered with a mobile Linear 
Accelerator (NOVAC7 by SIT) with a total dose of 21 Gy. An 
electron energy 7 to 9 MeV was used. A perspex shield was 
placed under the mammary gland, to reduce dose to the 
chest wall, heart and ipsilateral lung. Acute and late 
toxicities were evaluated one month after the treatment, 
then every three months for two years and every six months 
up to 5 years, according to RTOG scale while cosmetic 
outcomes was assessed by Harvard criteria. 
Results: The median follow-up was 54,6 months (range 5 to 
78). Mean age of the patients was 72,5 years (range: 62-80). 
Pathologic findings identified twenty-six patients as 
infiltrating ductal carcinoma and 5 as infiltrating lobular 
carcinoma. Patients presented N0 or N1mic status, except for 
two cases with N1a, and negative surgical margins. Average 
diameter of applicators was 60 mm (range 40-80). Treatment 
was successfully completed in all patients with an average 
lengthening of the operative time of about 20 minutes. At the 
long follow-up only one woman presented local relapse after 
55 months from IORT; she underwent re-excision followed by 
EBRT. Acute toxicity was G0 in 19 patients, G1 in 8 cases and 
G2 in 4 patients. No G3/G4 toxicities occurred. As early side 
effects 6 patients experienced seromas and one patient 
complained wound healing difficulties. G1/G2 late toxicity 
occurred in 6 patients. No lung or heart toxicities were 
observed. Cosmetic valuation was excellent/good in 25 
patients; 6 cases were scored as fairy/poor. 
Conclusions: IORT with a single dose in early breast cancer is 
feasible and well tolerated technique. In our experience it 
resulted in a significant shortening of radiotherapy time and 
gain in quality of life in elderly patients. In eligible cases 
(according to age and clinical staging) it seems a valid 
treatment option for adjuvant radiotherapy.  
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Purpose/Objective: To evaluate local control and cosmetic 
outcome of intra-operative radiation therapy (IORT) as an 
exclusive treatment of early stage breast cancer in patients 
with criteria as GEC-ESTRO (good candidates). 
Materials and Methods: From October 2008 to December 
2013, 100 patients underwent wide breast cancer excision or 
quadrantectomy followed by IORT on tumor bed with 
accelerated electrons (Novac 7 NRT) at the dose of 21Gy. 
Patients were aging at least 50 years with unicentric, 
unifocal, pT1-2  
Results: The average age was 63.89 (range 50–89) with an 
average follow up of 33 months (range 6–65). The pathologic 
stage of the lesions resulted pT1 in 82 cases (82%), in 
particular: 5 cases pT1a (6,1% on 82 cases), 38 pT1b (46,3%) 
and 39 pT1c (47,6%); 11 cases (11%) was pT2 with a diameter 
of 2,5 cm. 
The Grading was G1 in 21 cases (21%), G2 in 59 cases (59%) 
and G3 in 13 cases (13%). The toxicity, evaluated according 
to the EORTC-RTOG criteria, was G0 (37%) in 37 cases, G1 
(48%) in 48 cases, G2 in 6 case (6%); only 2 was G3 (2%). We 
observed 9 case of lymphocele (9%); there were no infections 
of the surgical wound nor any mastitis, neither in the treated 
quadrant nor in the other ones. 
We observed a light fibrosis in 14 cases (14%), moderate in 9 
(9%) and liponecrosis in 10 cases (10%). As regards local 
control, there was 2 (2%) local relapse and 1 second tumor. 
The global survival was 100%. 
Cosmetic outcome, evaluated in four levels (Danoff and co.), 
was excellent in 17 cases (17%), good in 63 (63%), sufficient 
in 11 cases (11%), never insufficient. 
Conclusions: The IORT in early breast cancer, at the doses 
used in this study on patients according to GEC-ESTRO 
criteria, provided itself as a secure technique, repeatable, 
with good local control and cosmetic outcome.  
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Purpose/Objective: To describe the initial experience of the 
first institution in Portugal in treating early breast cancer 
with intraoperative radiotherapy (IORT) with an electronic 
brachytherapy system. 
Materials and Methods: We retrospectively analyzed the 
data of 30 women who underwent intraoperative irradiation 
during breast conserving surgery between April 2012 and 
November 2014. Treatment was performed in a single 
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fraction for all patients, using a balloon applicator (ranging 
from 3-4 and 4-5cm in diameter) placed into the surgical bed. 
Distance from the applicator to the skin surface was verified 
intraoperatively through ultrasound monitoring. Energy of 50 
kV was used, in a dose of 20 Gy prescribed to the surface of 
the balloon, with a mean treatment duration of 550 seconds. 
Protection of the chest wall was performed with an 
attenuation disk that varied between 4 and 6 cm in diameter. 
Clinical, surgical and pathologic parameters, as well as the 
immediate and late toxicity were evaluated using the EORTC 
score. 
Results: The median age of the patients was 65 years (range 
42 to 89), stage pTisN0M0, pT1N0M0 and pT2N0M0. All patients 
had sentinel node assessment in the OR. Tumor size ranged 
between 0.4 and 2 cm. In 57% of the cases, the pathology 
revealed invasive ductal carcinoma without an extensive 
intra-ductal component. There were no post-operative 
complications and the immediate skin reaction was mild, 
without any grade 3/4 acute toxicity or delayed healing. Two 
cases of seroma and two cases of mild subcutaneous fibrosis 
were reported. With a median follow-up of 18 months, there 
were no local recurrences. There was one case of axillar 
recurrence one year after treatment. 
Conclusions: IORT using the Electronic Brachytherapy 
System® by Xoft as part of the conservative treatment of 
breast cancer is a safe procedure, with low morbidity. The 
low incidence of side effects as well as the short treatment 
time inside the OR has led to a growing interest in using this 
treatment solution. Following these patients will allow us 
monitoring any delayed reactions and subsequent cosmetic 
effect as well as the local control rate and survival.  
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Purpose/Objective: Intraoperative Electron Radiation 
Therapy (IOERT) has been demonstrated to be a good method 
of treatment of early breast cancer (BC) in selected patients 
(pts). In this study we evaluate the efficacy of a single dose 
of 18Gy given to the tumor bed during the surgery in order to 
reduce late toxicity with respect to the standard 21 Gy dose. 
Materials and Methods: From January 2009 to December 
2011, 72pts with diagnosis of early BC underwent IOERT as 
exclusive treatment after breast conservative surgery. The 
median age was 66 years (range 47–84). The criteria of 
eligibility were: tumors smaller than 10mm, sentinel node 
N0, negative surgical margins (≥5mm). All pts received 
standard dose of 18Gy with electrons beams of 4-10 Mev 
energy, given by a mobile linear dedicated accelerator. The 
choice of the collimator diameter was based on the primary 
tumor size and site (range 40mm-60mm): the most used was 
50mm, in 48\73 pts (66%). The protection of the thoracic wall 
was achieved using aluminum discs of diameter 7cm (range 5-
8). 
Results: With median follow up of 36 months (range 12-60) in 
all patients the acute and subacute toxicity was mild, there 
were no delays healing, wound dehiscence or infection. Late 
toxicity (fibrosis) at one year was G0 in 32pts(43%), G1 in 
26pts(36%),G2 in 15(20%). At 2years: G0 in 46pts(64%),G1 in 
22 pts(30%),G2 in 4pts(6%). At 3 years G0 in 52pts(73%),G1 in 
20pts(17%). At 4 years we have 23 pts in follow-up and only 
8pts(35%) have fibrosis G1. The aesthetic result is 
excellent/good in 87% pts , acceptable in 13%. One patient 
submitted local recurrence (1.4%) 
Conclusions: The short follow up and the limited number of 
patients do not allow us not to draw definitive conclusions, 
but at present patients are not experiencing an excess of 
local relapse with the 18Gy single IOERT dose. 
 
 
Proffered Papers: Donal Hollywood Award  
 
 
OC-0484   
Rescanning measurements in a 4D anthropomorphic 
phantom for evaluation of motion-mitigated, PBS proton 
therapy  
R.L. Perrin1, M. Peroni1, K. Bernatowicz1, A. Schaetti1, A.K. 
Knopf2, M. Zakova1, D. Oxley1, A. Mayor1, S. Safai1, T.C. 
Parkel3, D.C. Weber1, T. Lomax1 
1Paul Scherrer Institute (PSI), Centre for Proton Therapy, 
Villigen PSI, Switzerland  
2Institute of Cancer Research, Joint Department of Physics, 
London, United Kingdom 
3CSEM Centre Suisse d'Electronique et de Microtechnique SA 
(CSEM), Innovative Design, Landquart, Switzerland  
 
Purpose/Objective: To investigate the ability for rescanned 
PBS proton therapy to recover the dose distributions in 
mobile lung tumours, with phantom measurements within a 
dynamic,anthropomorphic,thorax phantom. 
Materials and Methods: For dosimetric measurements in a 
geometry similar to a lung cancer patient,a 
dynamic,anthropomorphic thorax phantom was employed. 
This consists of a tumour (wooden sphere) moving within an 
inflating lung,enclosed in a rib cage,complete with 
intercostal muscle and skin layers. Three planes of 
Gafchromic film in the coronal plane were used to measure 
the dose distributions resulting from PBS proton therapy for a 
range of rescan factors (≤8) and peak-to-peak motion 
amplitudes (4-10 mm). A PBS treatment was planned using an 
in-house planning system. The ITV was generated from the 
maximum excursion of the target as visualised on the mean 
projection CT calculated from a 4DCT scan. Two Single Field 
Uniform Dose (SFUD) fields (1.8 Gy prescribed dose) were 
employed at the following angles (gantry, couch): (-25,30), 
(45,0). To allow for up to 8-times scaled,volumetric re-
scanning per field, optimization of each field was performed 
with an 8-times higher cut-off for the lowest deliverable 
pencil beam weight. Prior to delivery,phantom and film 
positioning was checked and corrected using CT imaging,as 
performed for all patients. Table shifts were applied to 
match the ribs,and the tumour mid-ventilation position was 
aligned cranio-caudally by adjusting the position of the 
tumour in the lung. The phantom was programmed to move 
with a sinusoidal motion with maximum excursions of up to 4 
and 10 mm for deliveries with rescan factors between 1 and 
8. Reference films were acquired with the phantom and 
tumour stationary, and with a moving tumour with no 
rescanning. 
Results: Hot spots of up to 116% of the prescribed dose,with 
a pattern typically expected with the interplay effect,were 
clearly observed on the film with 10 mm motions (see Figure 
1),while with 4 mm motion, only a faint interplay pattern 
was observed. However,experimental error translating to an 
uncertainty in the homogeneity index (D5-D95) of typically 5% 
shadowed this result. With a rescan factor of 8, even in the 
case of 10 mm motion,dose homogeneities similar to those of 
the static case could be achieved (D5-D95 of static and 10 mm 
